The clinical efficacy of Adipromin for weight loss has been demonstrated in two randomized, double-blind, placebo-controlled clinical trials (RCTs), published in well-respected medical journals.*
Adipromin is not a stimulant or appetite suppressant. It does not interfere with absorption of fat or sugar, nor does it create a sense of fullness. Preclinical research indicates a dual mode of action:
Modulation of adipogenesis and lipolysis. Adipromin has been shown in preclinical research to inhibit lipid accumulation in adipocytes, slowing differentiation and maturation of adipocytes, and reducing intracellular triglyceride content. These actions are thought to be due to the demonstrated down-regulation of transcription factors PPAR‐gamma and C/EBP.†*
Increases Resting Energy Expenditure (REE). Adipromin has been shown in two preclinical animal studies† and one human clinical trial to increase resting energy expenditure.* The underlying mechanisms driving this increased metabolic activity have been elucidated and include notable increases in the production level of thermogenic markers (AMPKα, PGC1α and UCP1) and lipolytic (HSL) proteins.†
No other ingredient provides a comparable set of holistic benefits for weight management and cardiometabolic health:
Fast results; Significant weight loss in 14 days* Increased calorie burning in just 60 minutes*
Support for long-term weight loss (steady results over a 4-month study)*
Weight and inches reduction in both women and men*
Targets fat while improving lean body mass*
Significantly improved serum lipid profile*
Improved biomarkers and beneficial impact on key metabolic proteins that govern adipogenesis, lipolysis, and the browning of white adipose tissue.*
Adipromin has been shown in preclinical and clinical studies to be safe and well-tolerated.
